Repotrectinib
CAS 1802220-02-5Small Molecule
Overview
Repotrectinib is a small molecule active pharmaceutical ingredient (ChEMBL CHEMBL4298138).
Patent & exclusivity (US)
Per the FDA Orange Book (2 approved US products), the latest listed US patent on Repotrectinib expires 24 Jul 2036 and exclusivity 13 Jun 2031. Generic API sourcing typically opens up once these lapse.
Chemical identity
- IUPAC name
- (3R,11S)-6-fluoro-3,11-dimethyl-10-oxa-2,13,17,18,21-pentazatetracyclo[13.5.2.04,9.018,22]docosa-1(21),4(9),5,7,15(22),16,19-heptaen-14-one
- Canonical SMILES
- C[C@H]1CNC(=O)C2=C3N=C(C=CN3N=C2)N[C@@H](C4=C(O1)C=CC(=C4)F)C
- InChIKey
- FIKPXCOQUIZNHB-WDEREUQCSA-N
Verified Supplier Partner
Do you supply Repotrectinib? Get in front of buyers actively sourcing it.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.